Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)

Despite the heterogeneity of CD phenotypes and a potentially aggressive course of inadequately treated CD, treatment selection for newly diagnosed patients is currently based on clinical factors which do not define CD sub-types. Now, with additional biologic therapies for CD, there is a critical need for individual biochemical analysis both pre-treatment, and following induction to assess the probability of durable remission. These data will inform decisions on continued dosing of the current biologic, or whether addition of combination therapy or switching to a therapy with an alternative mechanism of action will be more beneficial.

The Food & Drug Administration (FDA) defines a companion diagnostic as a device that can identify patients most likely to benefit from a therapy or a device to monitor response with the purpose to adjust the treatment to achieve improved effectiveness.Our global aim is to develop a companion diagnostic (peripheral blood panel) that accurately predicts the probability of deep remission (clinical remission with MH) to anti-TNF and a protein (blood) biomarker panel that reproducibly distinguishes endoscopic MH from active (ulcerated) intestinal inflammation in patients with CD.

The long-term strategy is to utilize the "low-risk" anti-TNF specific module (protein panel) to personalize CD therapy. With the addition of new biologics for CD, patients with a low-risk inflammatory profile would not only be expected to achieve MH but also predicted to respond to treatment escalation strategies while avoiding or stopping the drug (if drug exposure is optimized) sooner in patients in which the protein profile predicts a low probability of deep remission with anti-TNF. As additional therapies are approved for pediatric CD, the priority would be to avoid anti-TNF in patients with a "high-risk" protein profile and specifically select therapies that target the patient's individual inflammatory signature. Additionally, the investigators expect the protein profile of patients failing to achieve deep remission to provide further insight into molecular mechanisms contributing to the continued inflammation and thereby directing the next therapeutic option.

Phase I - Cross-sectional Study (CD and Suspected IBD)

Inclusion criteria

• Age criteria: > 1 year to < 22 years of age
• Diagnosis of Crohn's disease, anti-TNF naïve, and colonoscopy scheduled OR
• Clinical suspicion for IBD (treatment naïve) and colonoscopy scheduled
• Permission of parent/guardian and assent or consent of research participant

Exclusion criteria

• Any prior treatment with an anti-TNF, such as infliximab, adalimumab, certolizumab or golimumab
• Known diagnosis of ulcerative colitis (UC) or inflammatory bowel disease-unspecified (IBD-U)
• Active or prior evidence of internal (abdominal/pelvic) penetrating fistula(e)
• Active intra-abdominal abscess or perianal abscess
• Active Clostridium difficile infection or other known enteric infection in last 2 weeks
• Current ileostomy or colostomy, extensive small bowel resection, ileoanal pouch or short bowel syndrome
• History of autoimmune disease (including autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis)
• Any condition that in the opinion of the PI will prevent the research participant from taking part in this study

Phase I - Cross-sectional Study (healthy volunteers)

Inclusion criteria

• Age criteria: > 1 year to < 22 years of age
• Any CCHMC patient
• Permission of parent/guardian and assent or consent of research participant

Exclusion criteria

• Known diagnosis of one or more of the following: irritable bowel syndrome, gastroesophageal reflux, constipation, BMI>95% for age, small intestinal bacterial overgrowth (SIBO) or history of intestinal polyps
• Received any antibiotic in the last 30 days or known viral or bacterial illness in the last 30 days
• Any NSAID use in the last 14 days
• History of an autoimmune disease (including diabetes, autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis)
• Any condition that in the opinion of the PI will prevent the research participant from taking part in this study

Phase II - Longitudinal Study of Participants with CD

Inclusion criteria

• Age criteria: > 1 year to < 22 years of age
• Diagnosis of Crohn's disease with:

• Luminal inflammation (ulcerations in ileum and/or colon visible by ileocolonoscopy) and
• Endoscopic evidence of active Crohn's disease (up to 90 days prior to starting anti-TNF) OR if no colonoscopy within 90 days then fecal calprotectin ≥250 µg/g or fecal lactoferrin >10 µg/g (<90 days from starting anti-TNF)
• Anti-TNF naïve
• Starting infliximab or adalimumab (or either biosimilar)
• Permission of parent/guardian and assent or consent of research participant

Exclusion criteria

• Crohn's disease limited to esophagus, stomach, duodenum or jejunum
• Prior treatment with infliximab, adalimumab, certolizumab or golimumab
• Known diagnosis of Ulcerative colitis (UC) or inflammatory bowel disease-unspecified (IBD-U)
• Active or prior evidence of internal (abdominal/pelvic) penetrating fistula(e)
• Active intra-abdominal abscess or perianal abscess
• Active Clostridium difficile infection or other known enteric infection in last 2 weeks
• Current ileostomy or colostomy, extensive small bowel resection, ileoanal pouch or short bowel syndrome
• History of autoimmune disease (including autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis)
• Contraindications to MRI scanning, such as metal implants/non-compatible medical devices or medical conditions
• Any condition that in the opinion of the PI will prevent the research participant from taking part in this study